Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 with or without ipilimumab in unresectable hepatocellular carcinoma
jRCT2071250129Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of PF-08634404 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Pfizer. Primary endpoints: Number of participants with adverse events, Number of participants with dose-limiting toxicities (DLTs) and 2 more. Started Feb 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2071250129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250129.